At the last check on Thursday, Kezar Life Sciences Inc.’s (NASDAQ:KZR) stock was up $0.08, moving up 7.01 percent to $1.22. The average number of shares traded per day over the past five days has been 662,673 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0200 fall in that time frame. In the last twenty days, the average volume was 396,708, while in the previous 50 days, it was 385,443.
Since last month, KZR stock retreated -12.86%. Shares of the company fell to $1.0900 on 09/21/23, the lowest level in the past month. A 52-week high of $9.00 was reached on 02/03/23 after having rallying from a 52-week low of $1.12. Since the beginning of this year, KZR’s stock price has dropped by -82.67% or -$5.8500, and marked a new high 3 times. However, the stock has declined by -86.45% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
KZR stock investors should be aware that Kezar Life Sciences Inc. (KZR) stock had its last reported insider trading activity 227 days ago on Feb 06. Morningside Venture Investment, the 10% Owner of the company, disposed of 40,000 shares for $6.88 on Feb 06. It resulted in a $275,320 divestment by the insider. Morningside Venture Investment sold 25,000 shares at an average price of $7.15 on Feb 03. The insider now owns 5,487,993 shares following the transaction. On Feb 02, 10% Owner Morningside Venture Investment sold 50,000 shares at $7.19 apiece. The transaction was valued at $359,500.
Financial Health
In the three months ended June 29, Kezar Life Sciences Inc.’s quick ratio stood at 17.70, while its current ratio was 17.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.04, and the total debt-to-equity ratio was 0.04. Based on annual data, KZR earned $1.19 million in gross profit and brought in $71.16 million in revenue.
In Kezar Life Sciences Inc.’s quarter-end financial report for June 29, it reported total debt of $9.95 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Kezar Life Sciences Inc. to report -$0.32 quarterly earnings, the actual figure was -$0.34 per share, beating the consensus estimate by -6.30%. During the quarter, the company generated -$28.3 million in EBITDA. The liabilities of Kezar Life Sciences Inc. were 31.1 million at the end of its most recent quarter ended June 29, and its total debt was $20.15 million. The value of shareholders’ equity is $72.69 million.
Technical Picture
This quick technical analysis looks at Kezar Life Sciences Inc.’s (KZR) price momentum. With a historical volatility rate of 59.59%, the RSI 9-day stood at 36.17% on 20 September.
With respect to its five-day moving average, the current Kezar Life Sciences Inc. price is down by -1.65% percent or -$0.0200. At present, KZR shares trade -19.05% below its 20-day simple moving average and -51.03% percent below its 100-day simple moving average. However, the stock is currently trading approximately -53.15% below its SMA50 and -83.98% below its SMA200.
Stochastic coefficient K was 9.06% and Stochastic coefficient D was 9.10%, while ATR was 0.0985. Given the Stochastic reading of 19.23% for the 14-day period, the RSI (14) reading has been calculated as 34.50%. As of today, the MACD Oscillator reading stands at -0.0322, while the 14-day reading stands at -0.1042.
Analyst Ratings
Kezar Life Sciences Inc. downgraded its rating on Kezar Life Sciences Inc. (NASDAQ: KZR) to an Equal weight in a note to investors on August 11, 2023. The analysts firm previously had an Overweight rating on the stock.Kezar Life Sciences Inc. (KZR) has been rated Overweight by analysts. According to 0 brokerage firms, KZR is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Kezar Life Sciences Inc. stock as buy, with 4 recommending it as overweight.
With a median target price of $15.00, the current consensus forecast for the stock is $4.00 – $18.00. Based on these forecasts, analysts predict Kezar Life Sciences Inc. (KZR) will achieve an average price target of $13.00.
